Biolumina
Network-owned
Address
1285 Avenue of the Americas, 6th Floor
New York, New York 10019
Web Address
Year Founded
2008
Parent Company
Omnicom Group, Inc.
Web Address
Full-time Employees 2022
Number of clients 2022
Offices
North America
1
Locations
New York, NY
Executives & Senior Management
Kirsten A. Kantak
President and CEO
Diane Iler-Smith
Chief Creative Officer
Brenda Aske
RPh, EVP, Managing Partner, Strategy
Senior Management
Kirsten A. Kantak
President and Chief Executive Officer
Agency 100 T-Shirt
Capabilities/Services Offered
Professional
Consumer
Direct Marketing
Med-ed
Med-Tech
Data/Analytics
Digital
New Roles
Roles Added
8
Roles
Kim Barke - EVP, Executive Creative Director
Client Roster
Novartis - Kisqali
Novartis - Lutathera
AstraZeneca - Tagrisso
AstraZeneca - Imfinzi
AstraZeneca - Global Lung Cancer (multiple tumor types)
AstraZeneca - IO Pipeline
AstraZeneca - Imfinzi + Lynparza
Janssen and Legend - Carvykti
Janssen - Erleada
Janssen - niraparib + Zytiga
Janssen - Prostate Franchise
Seagen - Tukysa
BeiGene - Brukinsa
Celldex Therapeutics - barzolvolimab
Menarini Stemline - elacestrant
Menarini Stemline - Elzonris
Sutro Biopharma
Verastem - avutometinib - defactinib
Growth
2022 Growth from Existing Clients
94%
2022 Growth from New Clients
6%
Trends and Challenges
Diversity and inclusion
Talent acquisition/retention
Managing growth
Payer-related challenges
Pricing-related issues
Getting an audience, virtually or otherwise, with HCPs
Keeping up with pace of innovation
Replenishing new-business pipeline
Procurement-related issues
Shrinking pharma budgets
Further diversification of services
Competition from consultancies and other non-traditional organizations
Pandemic-related disruptions
Healthcare Marketing Trends
More personalization of communications
Need to create more/better content/experiences
Heightened focus on payers
Scrutiny around social media
Impact of empowered patients/consumers
Intensified focus on analytics/ROI/measurement
Regulatory changes
Programs that go “beyond the pill”
Evolution of EHRs
Emphasis on specialty drugs/high-science categories
Adopting a data-science culture
More digital experimentation
Seizing opportunities around cannabis
Working from home
Ongoing fallout from pandemic
Creative Samples
